Cargando…
1790. Characteristics of Patients with Mpox Treated with Tecovirimat during the 2022 Outbreak in Puerto Rico
BACKGROUND: In June 2022, the first case of Mpox, was diagnosed in Puerto Rico, followed by a sharp increase in cases that peaked in August 2022. In total, 108 cases were confirmed during this period. Throughout this time period, Tecovirimat (Tpoxx) was already available upon request to the Puerto R...
Autores principales: | Gonzalez, Hector J Melendez, Rodriguez, Melissa Marzan, Gerena, Iris Cardona |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677632/ http://dx.doi.org/10.1093/ofid/ofad500.1619 |
Ejemplares similares
-
Tecovirimat Resistance in Mpox Patients, United States, 2022–2023
por: Smith, Todd G., et al.
Publicado: (2023) -
Tecovirimat for the treatment of severe Mpox in Germany
por: Hermanussen, Lennart, et al.
Publicado: (2023) -
2684. Characteristics of mpox patients treated with Tecovirimat: a single center review
por: Vargas, Robert, et al.
Publicado: (2023) -
Treatment of Mpox with Suspected Tecovirimat Resistance in Immunocompromised Patient, United States, 2022
por: Contag, Caitlin A., et al.
Publicado: (2023) -
Effectiveness estimates of three COVID-19 vaccines based on observational data from Puerto Rico
por: Robles-Fontán, Mónica M., et al.
Publicado: (2022)